Organon Building New Quality Affairs Group; New Jersey Plant To Close
This article was originally published in The Pink Sheet Daily
Executive Summary
The West Orange, N.J. facility’s closure will affect 220 employees and result in the discontinuation of three products. Organon hopes to offer 45-50 positions in quality affairs to affected staff.
You may also be interested in...
Organon Pharma Focus Is "Short Term": Strategic Decisions Later
Akzo Nobel wants to "fix pharma first" before it makes any decisions about long-term strategy in Rx sector, company says. Sales of Follistim are being held back by supply problems following shutdown of West Orange, N.J. plant.
Organon Pharma Focus Is "Short Term": Strategic Decisions Later
Akzo Nobel wants to "fix pharma first" before it makes any decisions about long-term strategy in Rx sector, company says. Sales of Follistim are being held back by supply problems following shutdown of West Orange, N.J. plant.
Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment
Despite expected “hit from lower sales” for pharmaceuticals in 2004, Akzo will continue to invest in R&D as “something stable,” company tells analysts. Potential 2004 launches include Organon’s Implanon and Variza, both pending at FDA.